AU2001275346A1 - Compositions, kits, and methods for identification and modulation of type i diabetes - Google Patents
Compositions, kits, and methods for identification and modulation of type i diabetesInfo
- Publication number
- AU2001275346A1 AU2001275346A1 AU2001275346A AU7534601A AU2001275346A1 AU 2001275346 A1 AU2001275346 A1 AU 2001275346A1 AU 2001275346 A AU2001275346 A AU 2001275346A AU 7534601 A AU7534601 A AU 7534601A AU 2001275346 A1 AU2001275346 A1 AU 2001275346A1
- Authority
- AU
- Australia
- Prior art keywords
- diabetes
- type
- kits
- compositions
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20970300P | 2000-06-05 | 2000-06-05 | |
US60/209703 | 2000-06-05 | ||
PCT/US2001/018418 WO2001094636A2 (en) | 2000-06-05 | 2001-06-05 | Compositions, kits, and methods for identification and modulation of type i diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001275346A1 true AU2001275346A1 (en) | 2001-12-17 |
Family
ID=22779905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001275346A Abandoned AU2001275346A1 (en) | 2000-06-05 | 2001-06-05 | Compositions, kits, and methods for identification and modulation of type i diabetes |
Country Status (9)
Country | Link |
---|---|
US (2) | US20020039736A1 (de) |
EP (1) | EP1290227B1 (de) |
JP (1) | JP2004510411A (de) |
AT (1) | ATE439453T1 (de) |
AU (1) | AU2001275346A1 (de) |
CA (1) | CA2411473A1 (de) |
DE (1) | DE60139553D1 (de) |
ES (1) | ES2331407T3 (de) |
WO (1) | WO2001094636A2 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060257932A1 (en) * | 1997-02-28 | 2006-11-16 | Yaron Ilan | Treatment of Crohn's disease |
JP2006503587A (ja) * | 2002-05-16 | 2006-02-02 | バンダービルト・ユニバーシティ | 自己免疫疾患の予測方法 |
GB0215509D0 (en) * | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
CA2527799A1 (en) * | 2003-05-30 | 2004-12-16 | Merck & Co., Inc. | Methods for identifying modulators of kinesin activity |
EP1538219A1 (de) * | 2003-12-04 | 2005-06-08 | Erasmus University Medical Center Rotterdam | Verfahren zur Diagnose oder Screening von Diabetes Mellitus Typ 1 |
EP1538218A1 (de) * | 2003-12-04 | 2005-06-08 | Erasmus University Medical Center Rotterdam | Verfahren zur Diagnose oder Untersuchung entzündlicher Krankheiten |
WO2006020755A2 (en) * | 2004-08-10 | 2006-02-23 | Beth Israel Deaconess Medical Center, Inc. | Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics |
US8119358B2 (en) | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
AU2006302031A1 (en) * | 2005-10-11 | 2007-04-19 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
WO2009015472A1 (en) * | 2007-07-30 | 2009-02-05 | London Health Sciences Centre Research Inc. | Methods to diagnose type 1 diabetes by measuring cytokine and/or chemokine expression profiles. |
EA201400710A1 (ru) | 2008-01-18 | 2015-03-31 | Президент Энд Феллоуз Оф Гарвард Колледж | Способы детекции признаков заболеваний или состояний в жидкостях организма |
EP2419536A4 (de) * | 2009-04-14 | 2012-09-05 | Merck Sharp & Dohme | Mikro-rna als biomarker für das eindringen von betazellen in die pankreasinseln |
KR20130041962A (ko) | 2010-07-23 | 2013-04-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 식작용 세포를 사용하여 질환 또는 상태를 검출하는 방법 |
US20120053073A1 (en) | 2010-07-23 | 2012-03-01 | President And Fellows Of Harvard College | Methods for Detecting Signatures of Disease or Conditions in Bodily Fluids |
US20130184178A1 (en) | 2010-07-23 | 2013-07-18 | President And Fellows Of Harvard College | Methods of Detecting Autoimmune or Immune-Related Diseases or Conditions |
CA2806304A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
WO2014164366A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting cancer |
EP3385717A3 (de) | 2013-03-09 | 2018-10-24 | Harry Stylli | Verfahren zum nachweis von prostatakrebs |
EP3693742B1 (de) | 2014-09-11 | 2022-04-06 | Harry Stylli | Verfahren zum nachweis von prostatakrebs |
CN116808063B (zh) * | 2023-07-05 | 2023-12-12 | 中国医学科学院北京协和医院 | 糖尿病的标志物及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
DE4209216A1 (de) * | 1992-03-21 | 1993-09-23 | Boehringer Mannheim Gmbh | Humaner t-zell-marker ht6 |
US7625697B2 (en) * | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
WO1999034209A1 (en) * | 1997-12-31 | 1999-07-08 | The Brigham And Women's Hospital, Inc. | DIAGNOSTIC AND THERAPEUTIC METHODS BASED UPON Vα24JαQ T CELLS |
-
2001
- 2001-06-05 AU AU2001275346A patent/AU2001275346A1/en not_active Abandoned
- 2001-06-05 EP EP01942050A patent/EP1290227B1/de not_active Expired - Lifetime
- 2001-06-05 WO PCT/US2001/018418 patent/WO2001094636A2/en active Application Filing
- 2001-06-05 AT AT01942050T patent/ATE439453T1/de not_active IP Right Cessation
- 2001-06-05 DE DE60139553T patent/DE60139553D1/de not_active Expired - Lifetime
- 2001-06-05 CA CA002411473A patent/CA2411473A1/en not_active Abandoned
- 2001-06-05 US US09/875,451 patent/US20020039736A1/en not_active Abandoned
- 2001-06-05 ES ES01942050T patent/ES2331407T3/es not_active Expired - Lifetime
- 2001-06-05 JP JP2002502176A patent/JP2004510411A/ja active Pending
-
2004
- 2004-09-14 US US10/941,712 patent/US20050164233A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1290227B1 (de) | 2009-08-12 |
JP2004510411A (ja) | 2004-04-08 |
ATE439453T1 (de) | 2009-08-15 |
WO2001094636A8 (en) | 2002-01-10 |
WO2001094636A2 (en) | 2001-12-13 |
EP1290227A1 (de) | 2003-03-12 |
CA2411473A1 (en) | 2001-12-13 |
ES2331407T3 (es) | 2010-01-04 |
US20020039736A1 (en) | 2002-04-04 |
US20050164233A1 (en) | 2005-07-28 |
DE60139553D1 (de) | 2009-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001275346A1 (en) | Compositions, kits, and methods for identification and modulation of type i diabetes | |
WO2001086002A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis | |
WO2001070979A3 (en) | Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer | |
WO2001053836A3 (en) | Identification, assessment, prevention, and therapy of prostate cancer | |
WO2001060860A3 (en) | Genes differentially expressed in human prostate cancer and their use | |
DE60141950D1 (de) | Vernetzte, nicht von pilzen kommende lipase enthaltende zusammensetzung und methoden zu deren verwendung | |
AU8112101A (en) | Non-imidazole aryloxypiperidines | |
DE60027606D1 (de) | Polyphenolisches protein enthaltende bioadhäsive zusammensetzung | |
ATE272059T1 (de) | Organische salze von isoleucyl-thiazolidin und - pyrrolidin und ihre verwendung als dipeptidylpeptidase-inhibitoren | |
SV2002000343A (es) | Composisiones farmaceuticas de inhibidores de la glucogeno fosforilasa ref. pc10882/20147/bb | |
AU3738597A (en) | Molecular model for vla-4 inhibitors | |
AU7585598A (en) | Raf kinase inhibitors | |
MXPA04004347A (es) | Nuevos fotoindicadores difuncionales. | |
WO2002044418A3 (en) | Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer | |
WO2004088943A3 (en) | Identifying and using indentities of communication partners deemed to be known to a user | |
WO2001018542A3 (en) | Identification, assessment, prevention, and therapy of ovarian cancer | |
WO2002044360A3 (en) | Modified arginine deiminase | |
WO2001042792A3 (en) | Diagnosis of cervical cancer using marker proteins | |
WO2002046765A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer | |
IL138688A0 (en) | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme | |
WO2001046697A3 (en) | Identification, assessment, prevention, and therapy of breast cancer | |
ATE421090T1 (de) | Neues screening-verfahren von modulatoren der bakteriellen transkription | |
DE60107457D1 (de) | Vorvernetzungshemmende zusammensetzung | |
HK1020211A1 (en) | Molecular model for vla-4 inhibitors vla-4 | |
WO2004009843A3 (de) | Nachweis von mikroorganismen |